Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Revvity Inc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.82, while Revvity Inc trades at $111.08 (market cap $12.53B). The key difference: Revvity Inc pays a 0.25% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Revvity Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | RVTY | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $16.61 | $117.75 |
52-Week Low | $10.26 | $82.26 |
Market Cap | — | $12.53B |
Enterprise Value | — | $15.02B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.
The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.
Revvity (RVTY) trades at $112.29, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key support at $110. The company demonstrates consistent earnings beats with Q1 2026 EPS of $1.06 exceeding expectations, maintaining solid profitability with 54.32% gross margins. Recent developments include AI integration partnerships with Anthropic and FDA clearance for new diagnostic tests, signaling innovation in life sciences.
RVTY presents a mixed outlook with analyst consensus leaning bullish (52% buy ratings) but trading above the $109.38 price target. While strong operational cash flow ($583M in 2025) and AI expansion provide upside potential, elevated P/E ratio (53.99) and declining net cash flow (-$243M in 2025) warrant caution amid competitive pressures in healthcare technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
